Soberana 02
Soberana 02
Soberana 02 (pronunciation: so-be-ra-na zero-two) is a COVID-19 vaccine candidate developed by the Finlay Institute in Cuba. The term "Soberana" is derived from the Spanish word for "sovereign," reflecting Cuba's aim for health sovereignty by developing its own vaccine.
Development
Soberana 02 is a conjugate vaccine, which means it uses a portion of the SARS-CoV-2 virus to trigger an immune response. The vaccine is combined with the tetanus toxoid to boost this response. It is currently in Phase III of clinical trials.
Efficacy
While the exact efficacy of Soberana 02 is still under investigation, preliminary results have shown promising results. The vaccine is administered in two doses, with a booster shot known as Soberana Plus given to those who have already contracted the virus.
Distribution
Cuba has announced plans to produce 100 million doses of Soberana 02 for domestic use and export. The country has also offered the vaccine to the ALBA countries (Bolivarian Alliance for the Peoples of Our America) and tourists visiting the island.
Related Terms
External links
- Medical encyclopedia article on Soberana 02
- Wikipedia's article - Soberana 02
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski